Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: J Heart Lung Transplant. 2020 Dec 29;40(4):298–306. doi: 10.1016/j.healun.2020.12.008

Table 3.

Univariate regression for mortality and morbidity in HT only patients (N = 32)

Characteristic at time of listing Post-transplant survival HR (95th CI) p-value Unplanned surgical procedure OR (95th CI) p-value Dialysis OR (95th CI) p-value
Age 1.01 (0.88–1.17) 0.850 1.08 (0.95–1.22) 0.252 1.06 (0.90–1.24) 0.503
Male gender 2.30 (0.27–19.22) 0.443 8.07 (0.90–72.08) 0.062 2.62 (0.27–25.29) 0.405
Heterotaxy 0.75 (0.88–6.34) 0.791 21 (0.45–9.86) 0.347 0.60 (0.06–5.93) 0.662
PLE 5.76 (1.11–29.88) 0.037 3.8 (0.90–16.00) 0.069 4.40 (0.69–28.11) 0.117
Sodium 0.97 (0.81–1.15) 0.684 0.72 (0.54–0.96) 0.027 0.90 (0.72–1.13) 0.359
Creatinine 0.70 (0.06–8.12) 0.778 1.42 (0.15–13.25) 0.757 2.95 (0.19–45.52) 0.439
Total bilirubin 0.96 (0.19–4.87) 0.958 0.46 (0.08–2.64) 0.388 0.50 (0.53–4.74) 0.549
Albumin 1.18 (0.39–3.59) 0.769 0.81 (0.31–2.14) 0.668 0.89 (0.26–3.04) 0.859
Platelets 0.99 (0.99–1.01) 0.455 1.00 (1.00–1.01) 0.518 0.99 (0.98–1.01) 0.311
Cirrhosis 5.08 (0.98–26.27) 0.052 10.5 (1.86–59.40) 0.008 6.67 (0.97–45.79) 0.054
Varices 1.90 (0.23–15.96) 0.552 4.44 (0.36–55.58) 0.247 2.40 (0.18–31.88) 0.507
Ascites 0.41 (0.05–3.45) 0.408 3.43 (0.61–19.40) 0.163 2.10 (0.30–14.87) 0.458
Splenomegaly 1.23 (0.24–6.35) 0.805 2.43 (0.47–12.54) 0.289 1.67 (0.24–11.44) 0.603
MELD-XI 0.92 (0.62–1.37) 0.696 0.83 (0.54–1.27) 0.392 1.05 (0.69–1.58) 0.824
Child Pugh 0.62 (0.29–1.37) 0.237 1.29 (0.69–2.43) 0.426 0.96 (0.42–2.16) 0.915
VAST 0.73 (0.27–1.94) 0.525 2.35 (0.98–5.65) 0.056 1.28 (0.48–3.42) 0.614

Cox-proportional method was used for survival outcomes, and logistic regression method for post-transplant morbidities.

Other variables included in analysis but not significant are: listing status, VAD, hospitalization, milrinone, dopamine, fibrosis on biopsy, stage 3 fibrosis on biopsy.